MarketCatalyst
← Back to Resources
Earnings

Parabilis Medicines Tops Q3 2026 Estimates

Revenue of $2.1M vs. $375K expected and EPS of -$0.36 vs. -$0.36.

Published Nov 12, 2026 · 8:52 AM ET · 2 min read

Parabilis Medicines (PBLS) topped estimates for the third quarter of 2026. Revenue was $2.1 million above the $375 thousand estimate, and EPS was -$0.36 in line with the -$0.36 estimate.

Shares rose 0.6% in premarket trading as of 8:43 a.m. ET, to $29.84 from a $29.65 close.

-$0.36
EPS vs. -$0.36 estimate
$2.1M
Revenue vs. $375K estimate
+0.6%
Shares premarket as of 8:43 a.m. ET

Q3 2026 scorecard

ParametersExpectedActualBeat/Miss
EPS-$0.36-$0.36In line
Revenue$375K$2.1MBeat by 464%
ChangeQoQ
EPS▲ 84%
Revenue▲ 2014%

By our calculation, revenue was $1.7 million above the estimate. The QoQ column compares with the previous quarter's revenue of $100 thousand and EPS of -$2.32.

GAAP results

  • Net loss. The company reported a net loss of $44.5 million on a GAAP basis.

Track record

  • EPS record. EPS beat the estimate in 0 of the last 2 reports, including this one.
  • Revenue record. Revenue beat the estimate in 1 of the last 2 reports.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of -$0.38 and revenue of $750 thousand next quarter, based on 2 analysts.
  • Estimate record. Whether Parabilis Medicines returns to beating EPS estimates, which it did in 0 of its last 2 reports.
  • Share reaction. How shares trade in the next regular session after the 0.6% gain in premarket trading.
  • Related coverage. See our reports on Hudbay Minerals, Accelerant, Ondas and Suburban Propane Partners.

Sources: Results are from Parabilis Medicines's Nov. 12, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Parabilis Medicines's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.

Parabilis Medicines Tops Q3 2026 Estimates